This trial was stopped early on the advice of the Data Monitoring and Ethics Committee
. This was because etoposide seemed to cause more side effects than the normal treatment, and patients also seemed to die more quickly. A similar trial which was carried out at the same time by the London Lung Cancer Group came up with the same results.
Researchers recommended that oral etoposide should not be used to treat this group of patients.